Search

Your search keyword '"Beck-Popovic, Maja"' showing total 336 results
Start Over Author "Beck-Popovic, Maja"
336 results on '"Beck-Popovic, Maja"'

51. Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams

Author

Vuattoux, Delphine, primary, Colomer-Lahiguera, Sara, additional, Fernandez, Pierre-Alain, additional, Jequier Gygax, Marine, additional, Choucair, Marie-Louise, additional, Beck-Popovic, Maja, additional, Diezi, Manuel, additional, Manificat, Sabine, additional, Latifyan, Sofiya, additional, Ramelet, Anne-Sylvie, additional, Eicher, Manuela, additional, Chabane, Nadia, additional, and Renella, Raffaele, additional

Published
2021
Full Text
View/download PDF

52. Corrigendum to 'Conservative management of retinoblastoma:Challenging orthodoxy without compromising the state of metastatic grace. 'Alive, with good vision and no comorbidity'' [Prog. Retina Eye Res. 73 (2019) 100764] (Progress in Retinal and Eye Research (2019) 73, (S1350946218300739), (10.1016/j.preteyeres.2019.05.005))

Author

Munier, Francis L., Beck-Popovic, Maja, Chantada, Guillermo L., Cobrinik, David, Kivelä, Tero T., Lohmann, Dietmar, Maeder, Philippe, Moll, Annette C., Carcaboso, Angel Montero, Moulin, Alexandre, Schaiquevich, Paula, Bergin, Ciara, Dyson, Paul J., Houghton, Susan, Puccinelli, Francesco, Vial, Yvan, Gaillard, Marie Claire, and Stathopoulos, Christina

Subjects
eye diseases
Abstract

The authors regret that Science Direct is not formatted to display the full content of the paper synopsis. This is now fixed with the publication of this corrigendum. List of contents 1. Introduction2. Epidemiology 2.1. Incidence2.2. Prevalence2.3. Predisposing factors for sporadic retinoblastoma3. Diagnosis 3.1. Presenting features3.2. Clinical examination and ancillary testing 3.2.1. Fundus documentation and fluorescein angiography3.2.2. Ultrasonic biomicroscopy (UBM)3.2.3. Optic coherence tomography (OCT)3.2.4. Magnetic Resonance Imaging (MRI)3.3. Classifications 3.3.1. Grouping of the eye at presentation (RE, IIRC, ICRB, COG, TNMH)3.3.2. Patient staging at presentation (IRSS, TNMH)3.3.3. Classification of retinoblastoma at relapse (RSU classification)3.4. Differential diagnosis3.5. Prenatal diagnosis of retinoblastoma3.6. Trilateral retinoblastoma 3.6.1. Incidence, early detection and screening3.6.2. Influence of the retinoblastoma treatment on the incidence of trilateral retinoblastoma3.6.3. Improved treatment of trilateral retinoblastoma: high-dose chemotherapy3.6.4. Differential diagnosis: pineal cysts3.7. Metastatic retinoblastoma 3.7.1. Diagnosis of metastatic retinoblastoma3.7.2. Treatment of metastatic retinoblastoma3.7.3. Influence of conservative retinoblastoma treatment in the occurrence of metastasis3.8. Second primary neoplasms 3.8.1. Incidence and mortality of second primary neoplasms3.8.2. Characteristics of secondary primary neoplasms3.8.3. Factors influencing the risk of secondary primary neoplasms 3.8.3.1. Genetic predisposition3.8.3.2. Influence of therapy3.8.3.2.1. Radiotherapy3.8.3.2.2. Chemotherapy3.8.4. Long-term follow-up in heritable retinoblastoma survivors 4. Retinoblastoma genesis 4.1. Mutational inactivation of the RB1 gene initiates retinoblastoma tumorigenesis4.2. Most retinoblastomas show more than two-hits4.3. RB1 mutations initiate tumorigenesis in the retinoblastoma cell-of-origin 4.3.1. First hints pointing towards a photoreceptor cell-of-origin4.3.2. Efforts to identify the retinoblastoma origin using genetically engineered mice4.3.3. Circumstantial and direct evidence for a cone precursor cell-of-origin4.3.4. Reconciling the cone precursor cell-of-origin with apparently contradictory observations4.4. Collaboration between RB1 inactivation and the cell-of-origin circuitry5. Retinoblastoma genetics and genetic counseling 5.1. Genetic presentations of retinoblastoma 5.1.1. Inherited heritable retinoblastoma (familial retinoblastoma) 5.1.1.1. Familial retinoblastoma with complete retinoblastoma5.1.1.2. Familial retinoblastoma with incomplete penetrance5.1.2. Isolated heritable retinoblastoma 5.1.2.1. Isolated bilateral retinoblastoma (full expressivity)5.1.2.2. Isolated retinoblastoma with genomic 13q14 deletion (reduced expressivity)5.1.3. Mosaic retinoblastoma5.1.4. Non-heritable retinoblastoma 5.1.4.1. Isolated unilateral retinoblastoma with somatic biallelic RB1 mutation5.1.4.2. Retinoblastoma without alterations of the RB1 gene 5.2. Genetic counseling and testing 5.2.1. Familial retinoblastoma5.2.2. Isolated bilateral retinoblastoma5.2.3. Isolated unilateral retinoblastoma 6. Clinical growth and seeding patterns 6.1. Retinoblastoma growth patterns 6.1.1. Classic growth patterns of primary retinoblastoma: endophytic, exophytic, mixed growth6.1.2. Rare variants of retinoblastoma 6.1.2.1. Cavitary retinoblastoma6.1.2.2. Diffuse infiltrating retinoblastoma6.1.2.3. Diffuse anterior retinoblastoma 6.2. Intra-ocular seeding 6.2.1. Vitreous seeding6.2.2. Retrohyaloid seeding6.2.3. Subretinal seeding6.2.4. Aqueous seeding 6.2.4.1. Prevalence of anterior chamber seeding6.2.4.2. Prevalence of anterior uvea invasion6.2.4.3. Invasion mechanisms of the aqueous humor 6.3. Retinoma/retinocytoma and phthisis bulbi 6.3.1. Prevalence and relationship with retinoblastoma6.3.2. Clinical features and risk of malignant transformation. 7. Conservative management of intraocular retinoblastoma 7.1. Pharmacokinetics 7.1.1. Intravenous drug delivery7.1.2. Intra-arterial drug delivery 7.1.2.1. Intraocular distribution of intra-arterial melphalan and topotecan7.1.2.2. Systemic adverse effects of intra-arterial delivered drugs7.1.3. Intravitreal drug delivery 7.1.3.1. Intraocular distribution of intravitreal melphalan7.1.3.2. Intraocular distribution of intravitreal topotecan7.1.4. Intracameral drug delivery7.1.5. Periocular drug delivery7.1.6. Suprachoroidal drug delivery7.2. Treatment modalities 7.2.1. Intravenous chemotherapy 7.2.1.1. Drug regimen and number of cycles7.2.1.2. Indications 7.2.1.2.1. Current indications7.2.1.2.2. Potential future indications 7.2.2. Treatment outcomes of intravenous chemotherapy 7.2.2.1. Relapse rate and role of consolidation by focal treatments7.2.2.2. Eye preservation without external beam radiotherapy7.2.3. Chemotherapy-related toxicity of intravenous chemotherapy 7.2.3.1. Expected toxicities7.2.3.2. Long-term toxicities7.2.4. Intra-arterial chemotherapy 7.2.4.1. Drug regimen and number of cycles7.2.4.2. Indications 7.2.4.2.1. Current indications7.2.4.2.2. Potential future indications7.2.4.3. Treatment outcomes 7.2.4.3.1. Recurrence rate and salvage therapy7.2.4.3.2. Eye preservation without external beam radiotherapy7.2.4.4. Adverse effects7.2.5. Intravitreal chemotherapy 7.2.5.1. Drug regimen and number of injections7.2.5.2. Safety7.2.5.3. Treatment outcomes7.2.5.4. Adverse effects7.2.6. Intracameral chemotherapy 7.2.6.1. Treatment outcomes7.2.6.2. Treatment-related adverse effects7.2.6.3. Potential alternatives to intracameral chemotherapy for aqueous seeding7.2.7. Periocular chemotherapy7.2.8. Focal treatments 7.2.8.1. Cryotherapy7.2.8.2. Hyperthermia7.2.8.3. Photocoagulation7.2.8.4. Brachytherapy 7.3. Disease and treatment-related complications 7.3.1. Amblyopia7.3.2. Cataract 7.3.2.1. Incidence7.3.2.2. Cataract surgery7.3.3. Rhegmatogenous retinal detachment 7.3.3.1. Incidence7.3.3.2. Surgical repair7.3.4. Secondary neovascularization7.3.5. Chorioretinal complications 7.3.5.1. Intravitreal melphalan-induced chorioretinopathy 7.3.5.1.1. Clinical presentation, classification system and incidence7.3.5.1.2. Risk factors associated with intravitreal melphalan-induced chorioretinopathy 7.3.5.1.2.1. Intravitreal concentration7.3.5.1.2.2. Para-vitreal injections7.3.5.1.2.3. Intraocular pigmentation7.3.5.1.2.4. Concomitant drug interactions 7.3.5.2. Choroidal occlusive vasculopathy 7.3.5.2.1. Clinical presentation, classification system and incidence.7.3.5.2.2. Factors associated with choroidal occlusive vasculopathy 7.4. Evaluation of quality of life8. Future directions and conclusion 8.1. Animal models8.2. Gene therapy8.3. Cell-of-origin targeted therapy8.4. Personalized therapy and liquid biopsy8.5. New drugs or combinations of drugs8.6. New Galenic formulation of known drugs8.7. Conclusion

Published
2020

53. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: a survey by the European Retinoblastoma group (EURbG)

Author

Dittner-Moormann, Sabine, primary, Reschke, Madlen, additional, Abbink, Floor, additional, Aerts, Isabelle, additional, Atalay, Hatice, additional, Bobrova, Nadezhda Fedorovna, additional, Biewald, Eva, additional, Brecht, Ines, additional, Caspi, Shani, additional, Cassoux, Nathalie, additional, Castela, Guilherme, additional, Diarra, Yelena, additional, Duncan, Catriona, additional, Ebinger, Martin, additional, Aldana, David Garcia, additional, Hadjistilianou, Theodora, additional, Kepák, Tomáš, additional, Klett, Artur, additional, Kiratli, Hayyam, additional, Maka, Erika, additional, Opocher, Enrico, additional, Rascon, Jelena, additional, Pawińska-Wąsikowska, Katarzyna, additional, Russo, Ida, additional, Rutynowska-Pronicka, Olga, additional, Sábado, Constantino, additional, Pacheco, Sonsoles San Roman, additional, Svojgr, Karel, additional, Timmermann, Beate, additional, Vishnevskia-Dai, Vicktoria, additional, Eggert, Angelika, additional, Ritter-Sovinz, Petra, additional, Bechrakis, Nicolaos, additional, Jenkinson, Helen, additional, Moll, Annette, additional, Munier, Francis, additional, Beck-Popovic, Maja, additional, Chantada, Guillermo, additional, Doz, Francois, additional, and Ketteler, Petra, additional

Published
2020
Full Text
View/download PDF

55. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

Author

Ambros, Inge M., primary, Tonini, Gian-Paolo, additional, Pötschger, Ulrike, additional, Gross, Nicole, additional, Mosseri, Véronique, additional, Beiske, Klaus, additional, Berbegall, Ana P., additional, Bénard, Jean, additional, Bown, Nick, additional, Caron, Huib, additional, Combaret, Valérie, additional, Couturier, Jerome, additional, Defferrari, Raffaella, additional, Delattre, Olivier, additional, Jeison, Marta, additional, Kogner, Per, additional, Lunec, John, additional, Marques, Barbara, additional, Martinsson, Tommy, additional, Mazzocco, Katia, additional, Noguera, Rosa, additional, Schleiermacher, Gudrun, additional, Valent, Alexander, additional, Van Roy, Nadine, additional, Villamon, Eva, additional, Janousek, Dasa, additional, Pribill, Ingrid, additional, Glogova, Evgenia, additional, Attiyeh, Edward F., additional, Hogarty, Michael D., additional, Monclair, Tom F., additional, Holmes, Keith, additional, Valteau-Couanet, Dominique, additional, Castel, Victoria, additional, Tweddle, Deborah A., additional, Park, Julie R., additional, Cohn, Sue, additional, Ladenstein, Ruth, additional, Beck-Popovic, Maja, additional, De Bernardi, Bruno, additional, Michon, Jean, additional, Pearson, Andrew D. J., additional, and Ambros, Peter F., additional

Published
2020
Full Text
View/download PDF

59. Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.

Author

Ladenstein, Ruth Lydia, primary, Poetschger, Ulrike, additional, Valteau-Couanet, Dominique, additional, Gray, Juliet, additional, Luksch, Roberto, additional, Balwierz, Walentyna, additional, Castel, Victoria, additional, Ash, Shifra, additional, Beck Popovic, Maja, additional, Laureys, Genevieve, additional, Chan, Godfrey Chi-Fung, additional, Ruud, Ellen, additional, Vettenranta, Kim, additional, Owens, Cormac, additional, Schroeder, Henrik, additional, Ambros, Peter F, additional, Sarnacki, Sabine, additional, Boterberg, Tom, additional, and Lode, Holger N., additional

Published
2020
Full Text
View/download PDF

62. Pédiatrie. Progrès récents et orientations futures de la thérapie avec cellules CAR-T en oncologie pédiatrique

Author

Ceppi, Francesco, Renella, Raffaele, Diezi, Manuel, Ansari Djaberi, Marc Georges, Duchosal, Michel A, Arber, Caroline, Kandalaft, Lana, Coukos, George, and Beck-Popovic, Maja

Subjects
ddc:618, T-Lymphocytes, Antigens, CD19, Cell- and Tissue-Based Therapy, Receptors, Antigen, T-Cell, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Child, Immunotherapy, Adoptive
Abstract

Combattre la leucémie en utilisant les armes immunologiques, via les anticorps et les lymphocytes, est une idée ancienne, qui a déjà connu un accomplissement dans la greffe de moelle osseuse. Pour limiter les effets néfastes sur d'autres organes (maladie du greffon contre l'hôte), des cellules T autologues peuvent être modifiées pour exprimer des récepteurs d'antigènes chimères synthétiques (CAR) avec spécificité antigénique. Dans le cadre d'essais cliniques, les cellules CAR-T anti-CD19 ont montré une efficacité importante dans les leucémies et les lymphomes B en rechute ou réfractaires. Dans cet article, nous décrivons les approches proposées, les résultats des essais cliniques, les effets secondaires et l'orientation future de ces thérapies dans les leucémies et d'autres cancers pédiatriques ainsi que leurs perspectives dans le contexte suisse.

Published
2019

66. Burkitts’s lymphoma – an atypical presentation

Author

Ziade Farah, von der Weid Nicolas, Beck-Popovic Maja, and Nydegger Andreas

Subjects
Burkitt’s lymphoma, Gastric, Stomach, Adolescent, Epstein barr virus, Krukenberg tumor, Pediatrics, RJ1-570
Abstract

Abstract Background In female adolescents and young adults, malignancies of the genital tract are the most frequent type of cancer, closely followed by Hodgkin’s and non-Hodgkin’s lymphomas. Case Presentation We report an unusual case of sporadic Burkitt’s lymphoma (BL) presenting with massive bilateral ovarian infiltration, peritoneal carcinomatosis and diffuse nodular lesions of the stomach and the intestine mimicking Krukenberg tumor. Diagnostic biopsies were obtained by endoscopy of the upper gastrointestinal tract. With intensive chemotherapy, complete remission was rapidly achieved, without life-threatening tumor lysis syndrome. Conclusion Besides metastatic gastric adenocarcinoma, BL is an important differential diagnosis in adolescents presenting with Krukenberg tumor.

Published
2012
Full Text
View/download PDF

67. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.

Author

Ladenstein, Ruth Lydia, primary, Poetschger, Ulrike, additional, Valteau-Couanet, Dominique, additional, Gray, Juliet, additional, Luksch, Roberto, additional, Balwierz, Walentyna, additional, Castel, Victoria, additional, Ash, Shifra, additional, Beck Popovic, Maja, additional, Laureys, Genevieve, additional, Chan, Godfrey Chi Fung, additional, Ruud, Ellen, additional, Vettenranta, Kim, additional, Owens, Cormac, additional, Schroeder, Henrik, additional, Loibner, Hans, additional, Ambros, Peter F, additional, Sarnacki, Sabine, additional, Boterberg, Tom, additional, and Lode, Holger N., additional

Published
2019
Full Text
View/download PDF

69. Retinoblastoma with late metastatic spread—a case report

Author

Hofer, Silvia, primary, Diebold, Joachim, additional, Temming, Petra, additional, Lohmann, Dietmar, additional, Howell, Jeremy, additional, Moulin, Alexandre, additional, Beck‐Popovic, Maja, additional, Sahm, Felix, additional, Milde, Till, additional, and Ecker, Jonas, additional

Published
2019
Full Text
View/download PDF

71. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Author

Ladenstein, Ruth, primary, Pötschger, Ulrike, additional, Valteau-Couanet, Dominique, additional, Luksch, Roberto, additional, Castel, Victoria, additional, Yaniv, Isaac, additional, Laureys, Genevieve, additional, Brock, Penelope, additional, Michon, Jean Marie, additional, Owens, Cormac, additional, Trahair, Toby, additional, Chan, Godfrey Chi Fung, additional, Ruud, Ellen, additional, Schroeder, Henrik, additional, Beck Popovic, Maja, additional, Schreier, Guenter, additional, Loibner, Hans, additional, Ambros, Peter, additional, Holmes, Keith, additional, Castellani, Maria Rita, additional, Gaze, Mark N, additional, Garaventa, Alberto, additional, Pearson, Andrew D J, additional, and Lode, Holger N, additional

Published
2018
Full Text
View/download PDF

73. Swiss Childhood Cancer Registry: Annual Report 2015/2016

Author

Pfeiffer, Verena, Redmond, Shelagh, Kuonen, Rahel, Sommer, Grit, Spycher, Ben, Singh, Parvinder, Michel, Gisela, Kuehni, Claudia, Niggli, Felix, Hengartner, Heinz, Beck Popovic, Maja, Von Der Weid, Nicolas, and Lamontagne-Müller, Isabelle

Subjects
360 Social problems & social services, 610 Medicine & health
Published
2017

76. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study

Author

Morgenstern, Daniel A., primary, Pötschger, Ulrike, additional, Moreno, Lucas, additional, Papadakis, Vassilios, additional, Owens, Cormac, additional, Ash, Shifra, additional, Pasqualini, Claudia, additional, Luksch, Roberto, additional, Garaventa, Alberto, additional, Canete, Adela, additional, Elliot, Martin, additional, Wieczorek, Aleksandra, additional, Laureys, Geneviève, additional, Kogner, Per, additional, Malis, Josef, additional, Ruud, Ellen, additional, Beck-Popovic, Maja, additional, Schleiermacher, Gudrun, additional, Valteau-Couanet, Dominique, additional, and Ladenstein, Ruth, additional

Published
2018
Full Text
View/download PDF

77. Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.

Author

Ladenstein, Ruth Lydia, primary, Poetschger, Ulrike, additional, Valteau Couanet, Dominique, additional, Gray, Juliet, additional, Luksch, Roberto, additional, Castel, Victoria, additional, Ash, Shifra, additional, Laureys, Genevieve, additional, Owens, Cormac, additional, Trahair, Toby, additional, Chan, Godfrey Chi Fung, additional, Ruud, Ellen, additional, Schroeder, Henrik, additional, Beck Popovic, Maja, additional, Loibner, Hans, additional, Schreier, Guenter, additional, Ambros, Peter F, additional, Sarnacki, Sabine, additional, Boterberg, Tom, additional, and Lode, Holger N., additional

Published
2018
Full Text
View/download PDF

78. The randomised induction for high-risk neuroblastoma comparing COJEC and N5-MSKCC regimens: Early results from the HR-NBL1.5/SIOPEN trial.

Author

Garaventa, Alberto, primary, Poetschger, Ulrike, additional, Valteau-Couanet, Dominique, additional, Castel, Victoria, additional, Elliott, Martin, additional, Ash, Shifra, additional, Chan, Godfrey Chi-Fung, additional, Laureys, Genevieve, additional, Beck Popovic, Maja, additional, Vettenranta, Kim, additional, Balwierz, Walentyna, additional, Schroeder, Henrik, additional, Owens, Cormac, additional, Cesen, Maja, additional, Papadakis, Vassilios, additional, Trahair, Toby, additional, Luksch, Roberto, additional, Schleiermacher, Gudrun, additional, Ambros, Peter F, additional, and Ladenstein, Ruth Lydia, additional

Published
2018
Full Text
View/download PDF

82. Low adherence to dietary recommendations in adult childhood cancer survivors

Author

Belle, Fabiën, primary, Wengenroth, Laura, additional, Weiss, Annette, additional, Sommer, Grit, additional, Beck Popovic, Maja, additional, Ansari, Marc, additional, Bochud, Murielle, additional, Kuehni, Claudia, additional, Ammann, R., additional, Angst, R., additional, Ansari, M., additional, Beck Popovic, M., additional, Bergstraesser, E., additional, Brazzola, P., additional, Greiner, J., additional, Grotzer, M., additional, Hengartner, H., additional, Kuehne, T., additional, Leibundgut, K., additional, Niggli, F., additional, Rischewski, J., additional, and von der Weid, N., additional

Published
2017
Full Text
View/download PDF

83. PASTEC: a prospective, single-center, randomized cross-over trial of pure physical versus physical/attentional activity in children with cancer

Author

Diezi, Manuel, Matthey, Sonia, Bourgit, David, Ballabeni, Pierluigi, Maeder, Stéphane, and Beck-Popovic, Maja

Abstract

Among disease- or treatment-related long-term effects of childhoodcancer, peripheral neuropathies, deficits in global coordination, balance, attention capacity andquality of life have been demonstrated. Several publications mention a potential benefit of phys-ical activity in improving long term outcome of such complications. Our study aimed primar-ily at evaluating the feasibility of a weekly physical activity program for children with cancerand secondly at assessing if the type of physical activity proposed could impact the pattern of improvement.

Published
2016

84. Pharmacokinetics of Intra-Arterial Melphalan in Patients withRecurrent or Progressive Retinoblastoma Treated on Spog-Rb-2011, A NationalPhase II Study of the Swiss Paediatric Oncology Group

Author

Diezi, Manuel, Mercier, Thomas, Galley, Maria Teresa, Decosterd, Laurent Arthur, Munier, Francis, and Beck-Popovic, Maja

Abstract

Since the 1990s, intravenous (iv) chemotherapy has been the system-atic first-line treatment used in the management of retinoblastoma, to reduce tumour volumeand render it accessible to focal treatments as well as to avoid enucleation and/or radiother-apy. This approach has allowed globe preservation in the majority of group A-C tumors and in19-60% of group D cases. Relapse or tumour progression in this group D patients constitute amajor concern for globe salvage. Techniques of local administration of chemotherapy, such asSelective Ophtalmic Artery Chemotherapy (SOAC) administration offers an interesting alter-native. We report here pharmacokinetic analysis of melphalan administered by SOAC in eightpatients, their clinical response to SOAC and observed toxicities.

Published
2016

85. Swiss Childhood Cancer Registry: Annual Report 2014/2015

Author

Pfeiffer, Verena, Redmond, Shelagh, Kuonen, Rahel, Sommer, Grit, Spycher, Ben, Schindler, Matthias, Singh, Parvinder, Michel, Gisela, Kuehni, Claudia, Niggli, Felix, Hengartner, Heinz, Beck Popovic, Maja, Von der Weid, Nicolas, and Lamontagne-Müller, Isabelle

Subjects
360 Social problems & social services, 610 Medicine & health
Published
2016
Full Text
View/download PDF

87. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment

Author

Munier, Francis L, primary, Mosimann, Pascal, additional, Puccinelli, Francesco, additional, Gaillard, Marie-Claire, additional, Stathopoulos, Christina, additional, Houghton, Susan, additional, Bergin, Ciara, additional, and Beck-Popovic, Maja, additional

Published
2016
Full Text
View/download PDF

89. Swiss Childhood Cancer Registry: Annual Report 2013/2014

Author

Schindler, Matthias, Mitter, Vera, Pfeiffer, Verena, Redmond, Shelagh, Wölfli, Priska, Kuonen, Rahel, Sommer, Grit, Spring, Marlen, Singh, Parvinder, Michel, Gisela, Kuehni, Claudia, Niggli, Felix, Hengartner, Heinz, Beck Popovic, Maja, Von Der Weid, Nicolas, and Lamontagne-Müller, Isabelle

Subjects
360 Social problems & social services, 610 Medicine & health
Published
2015

90. Global Retinoblastoma Presentation and Analysis by National Income Level

Author

Fabian, Ido Didi, Abdallah, Elhassan, Abdullahi, Shehu U., Abdulqader, Rula A., Adamou Boubacar, Sahadatou, Ademola-Popoola, Dupe S., Adio, Adedayo, Afshar, Armin R., Aggarwal, Priyanka, Aghaji, Ada E., Ahmad, Alia, Akib, Marliyanti N. R., Al Harby, Lamis, Al Ani, Mouroge H., Alakbarova, Aygun, Portabella, Silvia Alarcón, Al-Badri, Safaa A. F., Alcasabas, Ana Patricia A., Al-Dahmash, Saad A., Alejos, Amanda, Alemany-Rubio, Ernesto, Alfa Bio, Amadou I., Alfonso Carreras, Yvania, Al-Haddad, Christiane, Al-Hussaini, Hamoud H. Y., Ali, Amany M., Alia, Donjeta B., Al-Jadiry, Mazin F., Al-Jumaly, Usama, Alkatan, Hind M., All-Eriksson, Charlotta, Al-Mafrachi, Ali A. R. M., Almeida, Argentino A., Alsawidi, Khalifa M., Al-Shaheen, Athar A. S. M., Al-Shammary, Entissar H., Amiruddin, Primawita O., Antonino, Romanzo, Astbury, Nicholas J., Atalay, Hatice T., Atchaneeyasakul, La-ongsri, Atsiaya, Rose, Attaseth, Taweevat, Aung, Than H., Ayala, Silvia, Baizakova, Baglan, Balaguer, Julia, Balayeva, Ruhengiz, Balwierz, Walentyna, Barranco, Honorio, Bascaran, Covadonga, Beck Popovic, Maja, Benavides, Raquel, Benmiloud, Sarra, Bennani Guebessi, Nissrine, Berete, Rokia C., Berry, Jesse L., Bhaduri, Anirban, Bhat, Sunil, Biddulph, Shelley J., Biewald, Eva M., Bobrova, Nadia, Boehme, Marianna, Boldt, H.C., Bonanomi, Maria Teresa B. C., Bornfeld, Norbert, Bouda, Gabrielle C., Bouguila, Hédi, Boumedane, Amaria, Brennan, Rachel C., Brichard, Bénédicte G., Buaboonnam, Jassada, Calderón-Sotelo, Patricia, Calle Jara, Doris A., Camuglia, Jayne E., Cano, Miriam R., Capra, Michael, Cassoux, Nathalie, Castela, Guilherme, Castillo, Luis, Català-Mora, Jaume, Chantada, Guillermo L., Chaudhry, Shabana, Chaugule, Sonal S., Chauhan, Argudit, Chawla, Bhavna, Chernodrinska, Violeta S., Chiwanga, Faraja S., Chuluunbat, Tsengelmaa, Cieslik, Krzysztof, Cockcroft, Ruellyn L., Comsa, Codruta, Correa, Zelia M., Correa Llano, Maria G., Corson, Timothy W., Cowan-Lyn, Kristin E., Csóka, Monika, Cui, Xuehao, Da Gama, Isac V., Dangboon, Wantanee, Das, Anirban, Das, Sima, Davanzo, Jacquelyn M., Davidson, Alan, De Potter, Patrick, Delgado, Karina Q., Demirci, Hakan, Desjardins, Laurence, Diaz Coronado, Rosdali Y., Dimaras, Helen, Dodgshun, Andrew J., Donaldson, Craig, Donato Macedo, Carla R., Dragomir, Monica D., Du, Yi, Du Bruyn, Magritha, Edison, Kemala S., Eka Sutyawan, I. Wayan, El Kettani, Asmaa, Elbahi, Amal M., Elder, James E., Elgalaly, Dina, Elhaddad, Alaa M., Elhassan, Moawia M. Ali, Elzembely, Mahmoud M., Essuman, Vera A., Evina, Ted Grimbert A., Fadoo, Zehra, Fandiño, Adriana C., Faranoush, Mohammad, Fasina, Oluyemi, Fernández, Delia D. P. G., Fernández-Teijeiro, Ana, Foster, Allen, Frenkel, Shahar, Fu, Ligia D., Fuentes-Alabi, Soad L., Gallie, Brenda L., Gandiwa, Moira, Garcia, Juan L., García Aldana, David, Gassant, Pascale Y., Geel, Jennifer A., Ghassemi, Fariba, Girón, Ana V., Gizachew, Zelalem, Goenz, Marco A., Gold, Aaron S., Goldberg-Lavid, Maya, Gole, Glen A., Gomel, Nir, Gonzalez, Efren, Gonzalez Perez, Graciela, González-Rodríguez, Liudmira, Garcia Pacheco, Henry N., Graells, Jaime, Green, Liz, Gregersen, Pernille A., Grigorovski, Nathalia D. A. K., Guedenon, Koffi M., Gunasekera, D. Sanjeeva, Gündüz, Ahmet K., Gupta, Himika, Gupta, Sanjiv, Hadjistilianou, Theodora, Hamel, Patrick, Hamid, Syed A., Hamzah, Norhafizah, Hansen, Eric D., Harbour, J. William, Hartnett, M. Elizabeth, Hasanreisoglu, Murat, Hassan, Sadiq, Hassan, Shadab, Hederova, Stanislava, Hernandez, Jose, Hernandez, Lorelay Marie Carcamo, Hessissen, Laila, Hordofa, Diriba F., Huang, Laura C., Hubbard, G. B., Hummlen, Marlies, Husakova, Kristina, Hussein Al-Janabi, Allawi N., Ida, Russo, Ilic, Vesna R., Jairaj, Vivekaraj, Jeeva, Irfan, Jenkinson, Helen, Ji, Xunda, Jo, Dong Hyun, Johnson, Kenneth P., Johnson, William J., Jones, Michael M., Kabesha, Theophile B. Amani, Kabore, Rolande L., Kaliki, Swathi, Kalinaki, Abubakar, Kantar, Mehmet, Kao, Ling-Yuh, Kardava, Tamar, Kebudi, Rejin, Kepak, Tomas, Keren-Froim, Naama, Khan, Zohora J., Khaqan, Hussain A., Khauv, Phara, Kheir, Wajiha J., Khetan, Vikas, Khodabande, Alireza, Khotenashvili, Zaza, Kim, Jonathan W., Kim, Jeong Hun, Kiratli, Hayyam, Kivelä, Tero T., Klett, Artur, Komba Palet, Jess Elio Kosh, Krivaitiene, Dalia, Kruger, Mariana, Kulvichit, Kittisak, Kuntorini, Mayasari W., Kyara, Alice, Lachmann, Eva S., Lam, Carol P. S., Lam, Geoffrey C., Larson, Scott A., Latinovic, Slobodanka, Laurenti, Kelly D., Le, Bao Han A., Lecuona, Karin, Leverant, Amy A., Li, Cairui, Limbu, Ben, Long, Quah Boon, López, Juan P., Lukamba, Robert M., Lumbroso, Livia, Luna-Fineman, Sandra, Lutfi, Delfitri, Lysytsia, Lesia, Magrath, George N., Mahajan, Amita, Majeed, Abdul Rahim, Maka, Erika, Makan, Mayuri, Makimbetov, Emil K., Manda, Chatonda, Martín Begue, Nieves, Mason, Lauren, Mason, John O., Matende, Ibrahim O., Materin, Miguel, Mattosinho, Clarissa C. D. S., Matua, Marchelo, Mayet, Ismail, Mbumba, Freddy B., McKenzie, John D., Medina-Sanson, Aurora, Mehrvar, Azim, Mengesha, Aemero A., Menon, Vikas, Mercado, Gary John V. D., Mets, Marilyn B., Midena, Edoardo, Mishra, Divyansh K. C., Mndeme, Furahini G., Mohamedani, Ahmed A., Mohammad, Mona T., Moll, Annette C., Montero, Margarita M., Morales, Rosa A., Moreira, Claude, Mruthyunjaya, Prithvi, Msina, Mchikirwa S., Msukwa, Gerald, Mudaliar, Sangeeta S., Muma, Kangwa I., Munier, Francis L., Murgoi, Gabriela, Murray, Timothy G., Musa, Kareem O., Mushtaq, Asma, Mustak, Hamzah, Muyen, Okwen M., Naidu, Gita, Nair, Akshay Gopinathan, Naumenko, Larisa, Ndoye Roth, Paule Aïda, Nency, Yetty M., Neroev, Vladimir, Ngo, Hang, Nieves, Rosa M., Nikitovic, Marina, Nkanga, Elizabeth D., Nkumbe, Henry, Nuruddin, Murtuza, Nyaywa, Mutale, Obono-Obiang, Ghislaine, Oguego, Ngozi C., Olechowski, Andrzej, Oliver, Scott C. N., Osei-Bonsu, Peter, Ossandon, Diego, Paez-Escamilla, Manuel A., Pagarra, Halimah, Painter, Sally L, Paintsil, Vivian, Paiva, Luisa, Pal, Bikramjit P., Palanivelu, Mahesh Shanmugam, Papyan, Ruzanna, Parrozzani, Raffaele, Parulekar, Manoj, Pascual Morales, Claudia R., Paton, Katherine E., Pawinska-Wasikowska, Katarzyna, Pe'er, Jacob, Peña, Armando, Peric, Sanja, Pham, Chau T. M., Philbert, Remezo, Plager, David A., Pochop, Pavel, Polania, Rodrigo A., Polyakov, Vladimir G., Pompe, Manca T., Pons, Jonathan J., Prat, Daphna, Prom, Vireak, Purwanto, Ignatius, Qadir, Ali O., Qayyum, Seema, Qian, Jiang, Rahman, Ardizal, Rahman, Salman, Rahmat, Jamalia, Rajkarnikar, Purnima, Ramanjulu, Rajesh, Ramasubramanian, Aparna, Ramirez-Ortiz, Marco A., Raobela, Léa, Rashid, Riffat, Reddy, M. Ashwin, Reich, Ehud, Renner, Lorna A., Reynders, David, Ribadu, Dahiru, Riheia, Mussagy M., Ritter-Sovinz, Petra, Rojanaporn, Duangnate, Romero, Livia, Roy, Soma R., Saab, Raya H., Saakyan, Svetlana, Sabhan, Ahmed H, Sagoo, Mandeep S., Said, Azza M. A., Saiju, Rohit, Salas, Beatriz, San Román Pacheco, Sonsoles, Sánchez, Gissela L., Sayalith, Phayvanh, Scanlan, Trish A., Schefler, Amy C., Schoeman, Judy, Sedaghat, Ahad, Seregard, Stefan, Seth, Rachna, Shah, Ankoor S., Shakoor, Shawkat A., Sharma, Manoj K., Sherief, Sadik T., Shetye, Nandan G., Shields, Carol L., Siddiqui, Sorath Noorani, Sidi Cheikh, Sidi, Silva, Sónia, Singh, Arun D., Singh, Niharika, Singh, Usha, Singha, Penny, Sitorus, Rita S., Skalet, Alison H., Soebagjo, Hendrian D., Sorochynska, Tetyana, Ssali, Grace, Stacey, Andrew W., Staffieri, Sandra E., Stahl, Erin D., Stathopoulos, Christina, Stirn Kranjc, Branka, Stones, David K., Strahlendorf, Caron, Suarez, Maria Estela Coleoni, Sultana, Sadia, Sun, Xiantao, Sundy, Meryl, Superstein, Rosanne, Supriyadi, Eddy, Surukrattanaskul, Supawan, Suzuki, Shigenobu, Svojgr, Karel, Sylla, Fatoumata, Tamamyan, Gevorg, Tan, Deborah, Tandili, Alketa, Tarrillo Leiva, Fanny F., Tashvighi, Maryam, Tateshi, Bekim, Tehuteru, Edi S., Teixeira, Luiz F., Teh, Kok Hoi, Theophile, Tuyisabe, Toledano, Helen, Trang, Doan L., Traoré, Fousseyni, Trichaiyaporn, Sumalin, Tuncer, Samuray, Tyau-Tyau, Harba, Umar, Ali B., Unal, Emel, Uner, Ogul E., Urbak, Steen F., Ushakova, Tatiana L., Usmanov, Rustam H., Valeina, Sandra, van Hoefen Wijsard, Milo, Varadisai, Adisai, Vasquez, Liliana, Vaughan, Leon O., Veleva-Krasteva, Nevyana V., Verma, Nishant, Victor, Andi A., Viksnins, Maris, Villacís Chafla, Edwin G., Vishnevskia-Dai, Vicktoria, Vora, Tushar, Wachtel, Antonio E., Wackernagel, Werner, Waddell, Keith, Wade, Patricia D., Wali, Amina H., Wang, Yi-Zhuo, Weiss, Avery, Wilson, Matthew W., Wime, Amelia D. C., Wiwatwongwana, Atchareeya, Wiwatwongwana, Damrong, Wolley Dod, Charlotte, Wongwai, Phanthipha, Xiang, Daoman, Xiao, Yishuang, Yam, Jason C., Yang, Huasheng, Yanga, Jenny M., Yaqub, Muhammad A, Yarovaya, Vera A., Yarovoy, Andrey A., Ye, Huijing, Yousef, Yacoub A., Yuliawati, Putu, Zapata López, Arturo M., Zein, Ekhtelbenina, Zhang, Chengyue, Zhang, Yi, Zhao, Junyang, Zheng, Xiaoyu, Zhilyaeva, Katsiaryna, Zia, Nida, Ziko, Othman A. O., Zondervan, Marcia, and Bowman, Richard

Abstract

IMPORTANCE: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child’s life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. OBJECTIVES: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. DESIGN, SETTING, AND PARTICIPANTS: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. MAIN OUTCOMES AND MEASURES: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. RESULTS: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle–income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle–income countries vs upper-middle–income countries and HICs, 5.74 [95% CI, 4.30-7.68]). CONCLUSIONS AND RELEVANCE: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs.

Published
2020
Full Text
View/download PDF

91. Conservative treatment of diffuse infiltrating retinoblastoma: optical coherence tomographyassisted diagnosis and follow-up in three consecutive cases.

Author

Stathopoulos, Christina, Moulin, Alexandre, Gaillard, Marie-Claire, Beck-Popovic, Maja, Puccinelli, Francesco, and Munier, Francis L.

Abstract

Background/aims To report conservative therapy in diffuse infiltrating retinoblastoma (DIR) and describe specific optic coherence tomography (OCT) features of the tumour. Background/aims To report conservative therapy in diffuse infiltrating retinoblastoma (DIR) and describe specific optic coherence tomography (OCT) features of the tumour. Results Three patients (three eyes) were included, cases 1 and 3 with previous enucleation of the contralateral eye and case 2 with unilateral retinoblastoma referred after prior pars plana vitrectomy with silicone oil. Mean age at diagnosis was 7 years (range 14 months-14 years). Globe and vision preservation (Snellen visual acuity of 12.5/10) was achieved in case 3 with a recurrence-free follow-up of 33 months after first-line thermotherapy followed by salvage intra-arterial chemotherapy (IAC) plus focal treatments. Cases 1 and 2 were enucleated for progressive disease, case 1 after first-line intravenous chemotherapy (IVC) consolidated by focal therapies and salvage treatments given over 8 years of partial remission and case 2 after IAC, brachytherapy and intracameral chemotherapy. Neither showed any high-risk histopathological features, and no adjuvant chemotherapy was necessary. Both patients are alive without metastasis (mean follow-up of >10 years). Pathognomonic features of the tumour were revealed by OCT in all cases, showing infiltration of the ganglion cell layer and horizontal growth over the inner plexiform layer. Complete restoration of the retinal microanatomy was documented after retraction of the tumour following IVC in case 2 and IAC in case 3. Conclusion This is the first report of successful conservative management in DIR. OCT enabled diagnosis, delimitation of the tumour margins and monitoring of the treatment response in this context. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

93. Reply

Author

Francis, Jasmine H., primary, Abramson, David H., additional, Gaillard, Marie-Claire, additional, Marr, Brian P., additional, Beck-Popovic, Maja, additional, and Munier, Francis L., additional

Published
2016
Full Text
View/download PDF

95. Das Schweizer Kinderkrebsregister: Erfahrungen als nationales Krebsregister

Author

Michel, Gisela, Beck Popovic, Maja, Kuehni, Claudia E., Von Der Weid, Nicolas X., Egger, Matthias, Niggli, Felix, and Zwahlen, Marcel

Subjects
360 Social problems & social services, 610 Medicine & health
Abstract

Im Rahmen der Vernehmlassung zum nationalen Krebsregistrierungsgesetz werden Vor- und Nachteile einer nationalen Krebsregistrierung in der Schweiz erneut diskutiert. Das Schweizer Kinderkrebsregister (SKKR) blickt auf fast 40 Jahre Erfahrung als nationales Krebsregister für Kinder und Jugendliche zurück. Dieser Artikel erklärt die Besonderheiten von Krebserkrankungen bei Kindern, beschreibt die Erfahrungen des SKKR als nationales Krebsregister und zeigt den Nutzen der erhobenen Daten für Klinik, Forschung und Public Health.

Published
2013

96. Successful conservative treatment of massive choroidal relapse in 2 retinoblastoma patients monitored by ultrasound biomicroscopy and/or spectral domain optic coherence tomography.

Author

Stathopoulos, Christina, Gaillard, Marie-Claire, Puccinelli, Francesco, Maeder, Philippe, Hadjistilianou, Doris, Beck-Popovic, Maja, and Munier, Francis L.

Subjects
RETINOBLASTOMA, CANCER relapse, OPTICAL coherence tomography, ULTRASONIC imaging, MAGNETIC resonance imaging, PATIENTS, PREVENTION
Abstract

Purpose: To report the occurrence and management of secondary choroidal infiltration in two retinoblastoma (rb) patients. Methods:Fundus examination and imaging with spectral domain optical coherence tomography (SD-OCT), B-scan ultrasonography (B-scan), and ultrasound biomicroscopy (UBM). Results:Case 1: A 19-month-old girl with multifocal unilateral group B rb pretreated with intravenous chemotherapy (IVC) was referred for further management. At 3.5 years of age, routine 3-Tesla magnetic resonance imaging (3T-MRI) revealed an asymptomatic pinealoblastoma that underwent resection and adjuvant intensive IVC. Concomitant ophthalmic follow-up revealed a recurrence 8.3 × 2.8 mm at the posterior pole nasally to the optic disc on B-scan, localized within the choroid on SD-OCT and 3T-MRI. With high dose IVC ongoing, total regression of the choroidal mass was confirmed on SD-OCT already after 3 weeks. At 6-month follow-up, choroidal and pineal tumors were in complete remission. Sadly, the child died of intravascular disseminated coagulation-like disease after the 5th IVC. Case 2: A heavily pretreated 20-month-old girl with bilateral rb was referred for persistent vitreous seeding in her remaining eye (OD). Three months after intravitreal chemotherapy and chemothermotherapy, a hemorrhagic mass was observed inferior to the primary tumor. Two weeks later, an underlying peripheral choroidal mass 16 × 6 mm was documented by UBM and confirmed by 3T-MRI. Complete resolution was achieved 3 weeks after combined intra-arterial chemotherapy (IAC) of melphalan-topotecan. No recurrence or metastasis was observed at 34-month follow-up. Conclusion:Isolated massive choroidal invasion can be treated conservatively with IVC or IAC in selected cases. SD-OCT, UBM, and B-scan ultrasonography are instrumental in the detection and follow-up of choroidal lesions. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

97. Conservative treatment of diffuse infiltrating retinoblastoma: optical coherence tomography-assisted diagnosis and follow-up in three consecutive cases

Author

Stathopoulos, Christina, Moulin, Alexandre, Gaillard, Marie-Claire, Beck-Popovic, Maja, Puccinelli, Francesco, and Munier, Francis L

Abstract

Background/aimsTo report conservative therapy in diffuse infiltrating retinoblastoma (DIR) and describe specific optic coherence tomography (OCT) features of the tumour.MethodsRetrospective review of all DIR cases treated conservatively between 1998 and 2012.ResultsThree patients (three eyes) were included, cases 1 and 3 with previous enucleation of the contralateral eye and case 2 with unilateral retinoblastoma referred after prior pars plana vitrectomy with silicone oil. Mean age at diagnosis was 7 years (range 14 months–14 years). Globe and vision preservation (Snellen visual acuity of 12.5/10) was achieved in case 3 with a recurrence-free follow-up of 33 months after first-line thermotherapy followed by salvage intra-arterial chemotherapy (IAC) plus focal treatments. Cases 1 and 2 were enucleated for progressive disease, case 1 after first-line intravenous chemotherapy (IVC) consolidated by focal therapies and salvage treatments given over 8 years of partial remission and case 2 after IAC, brachytherapy and intracameral chemotherapy. Neither showed any high-risk histopathological features, and no adjuvant chemotherapy was necessary. Both patients are alive without metastasis (mean follow-up of >10 years). Pathognomonic features of the tumour were revealed by OCT in all cases, showing infiltration of the ganglion cell layer and horizontal growth over the inner plexiform layer. Complete restoration of the retinal microanatomy was documented after retraction of the tumour following IVC in case 2 and IAC in case 3.ConclusionThis is the first report of successful conservative management in DIR. OCT enabled diagnosis, delimitation of the tumour margins and monitoring of the treatment response in this context.

Published
2019
Full Text
View/download PDF

98. High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.

Author

Ladenstein, Ruth Lydia, Poetschger, Ulrike, Valteau Couanet, Dominique, Ash, Shifra, Beck Popovic, Maja, Balwierz, Walentyna, Boterberg, Tom, Chan, Godfrey Chi-Fung, Elliott, Martin, Kogner, Per, Lode, Holger N., Laureys, Genevieve, Luksch, Roberto, Malis, Josef, Owens, Cormac, Papadakis, Vassilios, Sarnacki, Sabine, Taschner-Mandl, Sabine, Schleiermacher, Gudrun, and Canete, Adela

Published
2023
Full Text
View/download PDF

99. Busulphan-melphalan is the superior myeloablative Therapy (mat) for high risk neuroblastoma: Results From the hr-nbl1/siopen trial

Author

Ladenstein, Ruth, Poetschger, Ulrike, Luksch, Roberto, Brock, Penelope, Castel, Victoria, Yaniv, Isaac, Papadakis, Vassilios, Laureys, Genevieve, Malis, Josef, Balwierz, Walentyna, Ruud, Ellen, Kogner, Per, Schrøder, Henrik, Forjaz De Lacerda, Ana, Beck-Popovic, Maja, Bician, Pavel, Garami, Miklos, Trahair, Toby, D.J. Pearson, Andrew, and Valteau-Couanet, Dominique

Abstract

O0103

Published
2011

100. Swiss Childhood Cancer Registry - Annual Report 2009/2010

Author

Mitter, Vera, Michel, Gisela (Author), Strippoli, Marie-Pierre, Rüegg, Corina, Rebholz, Cornelia, Feller, Martin, Hau, Eva, Reck, Marianne, Kuehni, Claudia, Niggli, Felix, Hengartner, Heinz, Beck-Popovic, Maja, and von der Weid, Nicolas

Subjects
360 Social problems & social services, 610 Medicine & health
Abstract

No abstract available., + ID der Publikation: unilu_6418 + Sprache: Englisch + Letzte Aktualisierung: 2019-02-19 17:17:46

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results